Progabide
Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated. EPHX1 hydration and ring opening of the oxetanyl moiety of AZD1979 and is inhibited by Progabide
General
Type : Not A\/B H target
Chemical_Nomenclature : 4-[[(4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylidene]amino]butanamide
Canonical SMILES : C1=CC(=CC=C1C(=NCCCC(=O)N)C2=C(C=CC(=C2)F)O)Cl
InChI : InChI=1S\/C17H16ClFN2O2\/c18-12-5-3-11(4-6-12)17(21-9-1-2-16(20)23)14-10-13(19)7-8-15(14)22\/h3-8,10,22H,1-2,9H2,(H2,20,23)
InChIKey : IBALRBWGSVJPAP-UHFFFAOYSA-N
Other name(s) : Halogabide,Gabren,Gabrene,SCHEMBL35328,SCHEMBL35329,SCHEMBL340485,SCHEMBL341677,CHEMBL287631,CHEBI:135422,ZINC13519914,ZINC18153101,DB00837
MW : 334.8
Formula : C17H16ClFN2O2
CAS_number : 62666-20-0
PubChem : 44115
UniChem : IBALRBWGSVJPAP-UHFFFAOYSA-N
IUPHAR :
Wikipedia :
Target
Families : Progabide ligand of proteins in family: Epoxide_hydrolase
Stucture :
Protein : human-EPHX1
References (2)
| Title : Discovery of a Novel Microsomal Epoxide Hydrolase-Catalyzed Hydration of a Spiro Oxetane - Li_2016_Drug.Metab.Dispos_44_1341 |
| Author(s) : Li XQ , Hayes MA , Gronberg G , Berggren K , Castagnoli N, Jr. , Weidolf L |
| Ref : Drug Metabolism & Disposition: The Biological Fate of Chemicals , 44 :1341 , 2016 |
| Abstract : Li_2016_Drug.Metab.Dispos_44_1341 |
| ESTHER : Li_2016_Drug.Metab.Dispos_44_1341 |
| PubMedSearch : Li_2016_Drug.Metab.Dispos_44_1341 |
| PubMedID: 27256986 |
| Gene_locus related to this paper: human-EPHX1 |
| Title : In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide - Kroetz_1993_Clin.Pharmacol.Ther_54_485 |
| Author(s) : Kroetz DL , Loiseau P , Guyot M , Levy RH |
| Ref : Clinical Pharmacology & Therapeutics , 54 :485 , 1993 |
| Abstract : Kroetz_1993_Clin.Pharmacol.Ther_54_485 |
| ESTHER : Kroetz_1993_Clin.Pharmacol.Ther_54_485 |
| PubMedSearch : Kroetz_1993_Clin.Pharmacol.Ther_54_485 |
| PubMedID: 8222491 |